Neurocrine Biosciences (NASDAQ: NBIX)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-10-31 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.590 | 0.840 | 0.2500 | ||||
REV | 341.310M | 378.200M | 36.890M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Neurocrine Biosciences (NASDAQ: NBIX) through any online brokerage.
Other companies in Neurocrine Biosciences’s space includes: Legend Biotech (NASDAQ:LEGN), Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS), Ionis Pharmaceuticals (NASDAQ:IONS) and Amgen (NASDAQ:AMGN).
The latest price target for Neurocrine Biosciences (NASDAQ: NBIX) was reported by Barclays on Friday, August 5, 2022. The analyst firm set a price target for 113.00 expecting NBIX to rise to within 12 months (a possible 8.61% upside). 20 analyst firms have reported ratings in the last year.
The stock price for Neurocrine Biosciences (NASDAQ: NBIX) is $104.04 last updated August 5, 2022, 8:00 PM UTC.
There are no upcoming dividends for Neurocrine Biosciences.
Neurocrine Biosciences’s Q3 earnings are confirmed for Monday, October 31, 2022.
There is no upcoming split for Neurocrine Biosciences.
Neurocrine Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.